SEC Form 4 · accession 0001858760-26-000008
Stoke Therapeutics, Inc. · STOK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas McCauley
Officer — Chief Scientific Officer
Period of report
Jul 15, 2026
Accepted (ET)
Jul 17, 2026 · 4:35 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001623526
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $29.91 | Jul 15, 2026 | A | 225,000 | A | — | Jul 14, 2036 | Common Stock | 225,000 | 225,000 | D |
Explanation of responses
- F1The stock option vests as to 1/4 of the total award on July 15, 2027, and as to 1/48 of the total award monthly thereafter, subject to the reporting person's continued service to the Issuer on each vesting date.